Valuation: BICO Group AB

Capitalization 1.23B 138M 116M 106M 101M 187M 12.46B 195M 488M 6.02B 516M 505M 21.02B P/E ratio 2025 *
-0.79x
P/E ratio 2026 * -8.66x
Enterprise value 1.24B 139M 117M 107M 102M 189M 12.56B 196M 492M 6.06B 520M 509M 21.2B EV / Sales 2025 *
0.8x
EV / Sales 2026 * 0.8x
Free-Float
62.25%
Yield 2025 *
-
Yield 2026 * -
1 day+3.08%
1 week+0.17%
Current month+0.99%
1 month-9.83%
3 months-13.07%
6 months-50.46%
Current year-17.28%
1 week 16.72
Extreme 16.72
17.58
1 month 16.24
Extreme 16.24
19.3
Current year 16.24
Extreme 16.24
21.06
1 year 16.24
Extreme 16.24
46.98
3 years 16.24
Extreme 16.24
95.8
5 years 16.24
Extreme 16.24
630
10 years 9
Extreme 9
630
Manager TitleAgeSince
Chief Executive Officer 54 2023-11-26
Director of Finance/CFO 41 2023-01-01
Director TitleAgeSince
Director/Board Member 73 2015-12-31
Director/Board Member 70 2019-12-17
Director/Board Member 57 2021-11-16
Change 5d. change 1-year change 3-years change Capi.($)
+3.08%+0.17%-49.62%-81.97% 138M
-0.98%-7.00%-5.22%-12.21% 190B
+1.51%-0.47%-17.85%+98.20% 173B
-1.10%-1.86%+4.42%-18.20% 150B
+0.82%-2.02%-29.59%+56.70% 111B
+0.79%-1.74%-29.86%-20.76% 53.87B
-0.75%-3.61%-0.17%-2.24% 44.03B
+2.15%-0.38%-14.06%+15.71% 36.61B
+2.78%-7.02%+5.46%+17.35% 36.79B
+0.74%-2.91%-7.80%-18.62% 35.58B
Average +0.90%-2.29%-14.43%+3.40% 83.03B
Weighted average by Cap. +0.26%-2.48%-10.72%+21.07%

Financials

2025 *2026 *
Net sales 1.55B 174M 146M 133M 127M 236M 15.72B 246M 616M 7.59B 651M 637M 26.52B 1.62B 181M 152M 139M 133M 246M 16.39B 256M 642M 7.92B 679M 665M 27.66B
Net income -1.55B -174M -146M -133M -127M -236M -15.73B -246M -616M -7.59B -651M -638M -26.54B -142M -15.89M -13.39M -12.21M -11.66M -21.64M -1.44B -22.48M -56.38M -695M -59.58M -58.36M -2.43B
Net Debt 10M 1.12M 943K 860K 821K 1.52M 101M 1.58M 3.97M 48.93M 4.2M 4.11M 171M 66.5M 7.44M 6.27M 5.72M 5.46M 10.13M 674M 10.53M 26.4M 325M 27.9M 27.33M 1.14B
Logo BICO Group AB
BICO Group AB, previously Cellink AB is a Sweden-based company, which is primarily involved in the healthcare industry. The Company focuses on the application areas of bioprinting, multiomics, cell line development, and diagnostics. The Company develops and markets technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. The Company’s operations divided in two segments: The Industrial Solutions segment that offers products within precision dispensing and biosensor technology for industrial customers, which make a high-capacity contribution to customers production; and The Laboratory Solutions segment that offers 3Dprinters, single- cell and liquid- dispensing instruments as well as services and consumables related to these products.
Employees
586
Date Price Change Volume
26-02-13 17.42 kr +3.08% 176,519
26-02-12 16.90 kr +0.30% 130,641
26-02-11 16.85 kr -4.10% 159,940
26-02-10 17.57 kr +2.33% 131,128
26-02-09 17.17 kr -1.27% 146,263
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
17.42SEK
Average target price
31.00SEK
Spread / Average Target
+77.96%

Quarterly revenue - Rate of surprise